|
1/2023
vol. 25
abstract:
Review paper
Adult pneumococcal vaccination – new opportunities
Ernest Kuchar
1
 ,
Joanna Chorostowska-Wynimko
2
,
Leszek Czupryniak
3
,
Andrzej Fal
4, 5
,
Robert Flisiak
6
,
Artur Mamcarz
7
,
Aneta Nitsch-Osuch
8
,
Anna Skoczyńska
9
,
Marcin Stajszczyk
10
,
Jacek Wysocki
11
,
Dominik Golicki
13
,
Adam Antczak
15
- Department of Paediatrics with Clinical Assessment Unit, Medical University of Warsaw, Warsaw, Poland
- Department of Genetics and Clinical Immunology, National Institute of Tuberculosis and Lung Diseases, Warsaw, Poland
- Department of Diabetology and Internal Medicine, Medical University of Warsaw, Warsaw, Poland
- Department of Allergology, Lung Diseases and Internal Diseases, Central Clinical Hospital of the Ministry of Interior and Admin-istration, Warsaw, Poland
- Faculty of Medicine, Collegium Medicum, Cardinal Stefan Wyszynski University, Warsaw, Poland
- Department of Infectious Diseases and Hepatology, Medical University of Bialystok, Bialystok, Poland
- 3rd Department of Internal Diseases and Cardiology, Faculty of Medicine, Medical University of Warsaw, Warsaw, Poland
- Department of Social Medicine and Public Health, Medical University of Warsaw, Warsaw, Poland
- National Reference Centre for Bacterial Meningitis (KOROUN), Department of Epidemiology and Clinical
Microbiology, National Medicines Institute, Warsaw, Poland
- Department of Rheumatology and Autoimmune Diseases, Silesian Centre for Rheumatology, Orthopaedics and Rehabilitation, Ustron, Poland
- Chair and Department of Health Prevention, Faculty of Health Sciences Poznan University of Medical Sciences, Poznan, Poland
- Pfizer Polska Sp. z o.o., Warsaw, Poland
- Chair and Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland
- HealthQuest Sp. z o.o., Warsaw, Poland
- Department of General and Oncological Pulmonology, Medical University of Lodz, Lodz, Poland
Family Medicine & Primary Care Review 2023; 25(1): 93–101
Online publish date: 2023/03/31
PlumX metrics:
Pneumococcal infections (Streptococcus pneumoniae) remain a significant epidemiological problem globally. Although an invasive pneumo-coccal disease (IPD), which includes meningitis, sepsis and pneumonia with bacteremia, is the most severe form of pneumococcal infection, the main bur-den in terms of morbidity and mortality is associated with community-acquired pneumonia in the elderly. The epidemiology of infections caused by S. pneumoniae serotypes can change naturally in time and by universal vaccination implementation. The proportion of infections caused by serotypes not contained in any available vaccines is constantly increasing. These changes stimulate the development of new vaccines and ensure the broadest possible protection against S. pneumoniae infections. There is a need to raise awareness of the burden of pneumococcal disease in adults and the vaccines used for prophylaxis for pneumococcal infection.
The article discusses the pneumococcal infection burden in the adult population and the factors that raise the risk of infections. We characterised available vaccines for adults, highlighting the significant differences between the conjugated and unconjugated polysaccharide vaccines. Current epidemiological data on pneumococcal infections in Europe and Poland is presented. The latest 20-valent pneumococcal conjugate vaccine (PCV20) is described, and the most recent Advisory Committee on Immunization Practices (ACIP) recommendations on primary prevention and the current implementation of vaccination against pneumococcal infections in the adult population in Poland are discussed.
keywords:
Streptococcus pneumoniae, pneumococcal vaccines, adult
|
|
